| 000 | 01629 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517044212.0 | ||
| 264 | 0 | _c20160219 | |
| 008 | 201602s 0 0 eng d | ||
| 022 | _a1944-7884 | ||
| 024 | 7 |
_a10.1097/QAI.0000000000000777 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDumond, Julie B | |
| 245 | 0 | 0 |
_aBrief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results. _h[electronic resource] |
| 260 |
_bJournal of acquired immune deficiency syndromes (1999) _cDec 2015 |
||
| 300 |
_a510-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xadministration & dosage |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aCarbamates _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFurans |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLopinavir _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aSulfonamides _xadministration & dosage |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _aRigdon, Joseph | |
| 700 | 1 | _aMollan, Katie | |
| 700 | 1 | _aTierney, Camlin | |
| 700 | 1 | _aKashuba, Angela D M | |
| 700 | 1 | _aAweeka, Francesca | |
| 700 | 1 | _aCollier, Ann C | |
| 773 | 0 |
_tJournal of acquired immune deficiency syndromes (1999) _gvol. 70 _gno. 5 _gp. 510-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/QAI.0000000000000777 _zAvailable from publisher's website |
| 999 |
_c25127676 _d25127676 |
||